Acton, Massachusetts, United States
With over 20 years of experience in pharma and biotech, I am a Medical Affairs leader passionate about advancing scientific exchange, evidence generation, and patient outcomes. Through MC4U Consulting LLC, I partner with small and mid-size biopharma companies to design and execute impactful Medical Affairs strategies. My services include: Scientific Communication Platforms (SCPs) and publication planning Evidence generation (clinical, RWE, HEOR) Payer and market access support (AMCP dossiers, payer tools, stakeholder engagement) Digital and omnichannel medical strategies Medical Affairs metrics, dashboards, and performance KPIs Launch readiness planning and execution The impact: helping growing organizations scale their Medical Affairs functions with efficiency, compliance, and purpose—delivering measurable value to stakeholders and improving patient care. #MedicalAffairs #PharmaStrategy #BiotechConsulting #MarketAccess #EvidenceGeneration
*Serve as the Publication and Medical Communications Lead for the IBD program *Lead development of strategic global publication plan *Collaborate with external authors and journals in compliance with ICMJE, GPP and SOPs *Vendor partnership to execute the tactical plan *Lead the planning and execution of the integrated congress plans *Lead the development of scientific communication platform (SCP) and core communication objectives *Serve as the medical approver for medical materials *Generate scientific content for internal and external medical communcations *Oversee budget, financial forecasting and vendor management
• Founded MC4U Consulting LLC, specializing in Medical Affairs Strategy and Execution. • Develop comprehensive Market Access and Payer Strategies to enhance client engagement. • Execute Medical Communications strategies to effectively convey complex medical information. • Provide Clinical Pharmacist support to optimize healthcare outcomes for clients.
Advised executive leadership on medical strategy, clinical evidence planning, and scientific positioning to drive market differentiation and commercial growth.
Defined global medical affairs strategy for late-stage metabolic and rheumatology assets, directly enabling launch excellence and commercial readiness.